Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
Amazon's cloud computing unit will invest $13 billion (£10.5bn) in India by the end of this decade, doubling down on its past investments to cater to the growing demand for such services in one of Asia's fastest-growing economies.
This comes on top of its $6.5bn (£5.2bn) investment in e-commerce in India, where it has rapidly expanded over the years but faces a strict regulatory environment that forces it to run only a marketplace.
The latest investment will be used to build its cloud infrastructure in India and will support over 100,000 full-time jobs annually, Amazon Web Services (AWS) said in a statement on Thursday (18). With this, the total planned investment in India adds up to about $16.4bn (£13.2bn) by 2030.
The company already runs two data centers in the Indian subcontinent - one in Mumbai which was launched in 2016, and another in Hyderabad, which started in 2022.
The cloud platform offers more than 200 services, including storage, networking and artificial intelligence.
Amazon's move comes as India steps up efforts to attract more big-ticket investments in the digital space to address the spike in demand for data storage and services from corporate and government bodies.
India's public cloud services market is expected to touch $13bn (£10.5bn) by 2026, climbing at a compound annual growth rate of 23.1 per cent for 2021-26, according to market intelligence provider IDC.
A host of global companies, including Microsoft and Alphabet Inc's Google, have ramped up cloud investments in India in recent years amid New Delhi's push to gain stricter oversight of Big Tech firms by nudging to store data locally.
The country is currently drafting a cloud and data center policy to regulate the sector. India's broader tech sector, too, has attracted high-profile investments in recent months.
US networking equipment maker Cisco Systemsearlier this month said it would start manufacturing from India to diversify its global supply chain, while Apple Inc supplier Foxconn will invest $500m (£402m) to set up plants in the southern Indian state of Telangana.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.